Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

被引：20
|
作者：
Kelley, Michael J. [1 ,2 ,3 ]
Jha, Gautam [4 ]
Shoemaker, Debra [2 ]
Herndon, James E., II [2 ]
Gu, Lin [2 ]
Barry, William T. [2 ,5 ]
Crawford, Jeffrey [1 ,2 ]
Ready, Neal [1 ,2 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA
[3] Durham Vet Affairs Med Ctr, Med Serv, Durham, NC USA
[4] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
[5] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
来源：
CANCER INVESTIGATION | 2017年 / 35卷 / 01期
关键词：
Non-small cell lung cancer; Src; gene expression; ERLOTINIB; TRIAL;
D O I：
10.1080/07357907.2016.1253710
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients hadminor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.
引用
收藏
页码：32 / 35
页数：4
相关论文
共 50 条
  • [41] A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Han, Ji-Youn
    Lee, Soo-Hyun
    Yoo, Nam Jin
    Lee, Suk Hyung
    Moon, Yoon Joo
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1553 - 1560
  • [42] Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study
    Pectasides, D
    Mylonakis, N
    Farmakis, D
    Nikolaou, M
    Koumpou, M
    Katselis, I
    Gaglia, A
    Kostopoulou, V
    Karabelis, A
    Kosmas, C
    ANTICANCER RESEARCH, 2003, 23 (5B) : 4205 - 4211
  • [43] PHASE II STUDY OF TWO ERIBULIN REGIMENS IN COMBINATION WITH ERLOTINIB IN PATIENTS (PTS) WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Geater, S. L.
    Ianotti, N.
    Thongprasert, S.
    Spira, A.
    Smith, D.
    Lee, V.
    Lim, W-T.
    Gopalakrishna, P.
    Reynolds, C.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2012, 23 : 393 - 393
  • [44] A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
    Felip, Enriclueta
    Rojo, Federico
    Reck, Martin
    Heller, Astrid
    Klughammer, Barbara
    Sala, Gemma
    Cedres, Susana
    Peralta, Sergio
    Maacke, Heiko
    Foernzler, Dorothee
    Parera, Marta
    Moecks, Joachim
    Saura, Cristina
    Gatzemeier, Ulrich
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2008, 14 (12) : 3867 - 3874
  • [45] Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients
    Ankit Madan
    Benjamin S. Jones
    Rodolfo Bordoni
    Mansoor N. Saleh
    Mary S. Jerome
    Deborah K. Miley
    Bradford E. Jackson
    Francisco Robert
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 509 - 515
  • [46] A Randomized Phase II Study of Gefitimb Plus Simvastatin versus Gefitimb Alone in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Won, Young-Woong
    Han, Ji Youn
    Lee, Soo-Hyun
    Yoo, Nam Jin
    Lee, Suk Hyung
    Moon, Yoon Joo
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S385 - S385
  • [47] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2018, 13 (03) : 399 - 407
  • [48] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Hannah A. Blair
    Targeted Oncology, 2018, 13 : 399 - 407
  • [49] CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED WITH ADJUVANT CHEMOTHERAPY
    Valdes, Mario
    Goss, Glenwood
    Nicholas, Garth
    Wheatley-Price, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S583 - S583
  • [50] Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer
    Zhou, Songwen
    Ren, Shengxiang
    Yan, Lianghua
    Zhang, Ling
    Tang, Liang
    Zhang, Jie
    Zhou, Caicun
    RESPIROLOGY, 2009, 14 (05) : 709 - 715
12345